<DOC>
	<DOC>NCT00034463</DOC>
	<brief_summary>This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.</brief_summary>
	<brief_title>ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologic or cytologic diagnosis of metastatic or locally advanced cancer Prior chemotherapy is allowed Adequate bone marrow, liver and kidney function Prior treatment with ALIMTA Brain metastasis Pregnancy or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>metastatic cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>